Responding to the news of the Oxford-AstraZeneca jab facing a new set of trials, the developers of the pioneering Russian Sputnik V vaccine have suggested combining the two vaccines to drastically improve AstraZeneca’s efficacy.
The idea appeared on the official Twitter page of the Sputnik V vaccine, which is financed by the Russian Direct Investment Fund (RDIF), on Thursday.
Current full dose AstraZeneca regimen resulted in 62% efficacy. If they go for a new clinical trial, we suggest trying a regimen of combining the AZ shot with the #SputnikV human adenoviral vector shot to boost efficacy. Combining vaccines may prove important for revaccinations.
— Sputnik V (@sputnikvaccine) November 26, 2020
“We suggest trying a regimen of combining the AZ shot with the #SputnikV human adenoviral vector shot to boost efficacy,” said the message, referring to AstraZeneca’s published trial results.
Combining vaccines may prove important for revaccinations.
The offer follows comments from AstraZeneca’s CEO Pascal Soriot to Bloomberg on Thursday, who admitted the company will have to “do an additional study” before its vaccine is ready, given that its trials have resulted in varying efficacy, depending on the dose.
Despite a number of unexplained inconsistencies during the trials, on Monday AstraZeneca said it would seek emergency authorization for its coronavirus vaccine. With the British-Swedish developer rushing to roll out an inoculation, RT on Wednesday compiled a list of seven questions for AstraZeneca, asking the company to dispel doubts about the safety and efficacy of its jab.